Can Moderna actually make a vaccine for the common cold? (And should it?)
Moderna has spent the last year and a half, since their Covid-19 shots first neared authorization, steadily announcing new vaccine projects. Most of these have been welcomed by vaccinologists and public health researchers, who long struggled to get industry interested in certain pathogens such as Nipah or EBV, despite the threat they posed.
But on Tuesday, the mRNA biotech disclosed a new program that had some in the vaccine world scratching their chins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.